EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ApoE4 Upregulates GSK ‐3β to Aggravate Alzheimer‐Like Pathologies and Cognitive Impairment in Type 2 Diabetic Mice

Yuying Wang iD, Yang Gao iD, Yarong Wang, Fuqiang Zhang, Fei Sun, Xin Wang, Jiazhao Xie, Zhipeng Xu, Junjian Zhang, Haibo Xu iD, Yao Zhang, Jian-Zhi Wang

CNS Neuroscience & Therapeutics · 2025

DOI: 10.1111/cns.70575 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Yuying Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Ministry of Education for Neurological Disorders, Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, …. Hauptthemen laut MEDLINE: Glycogen Synthase Kinase 3 beta, Apolipoprotein E4, Diabetes Mellitus, Type 2, Alzheimer Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation General Program, Guangdong Provincial Key S&T Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The apolipoprotein E (ApoE) ε4 allele and type 2 diabetes mellitus (T2DM) are independent risk factors for Alzheimer's disease (AD), the most prevalent neurodegenerative disorder in the elderly. The T2DM patients carrying the ApoE ε4 allele exhibit heightened activation of platelet glycogen synthase kinase‐3β (GSK‐3β), a key downstream kinase in the insulin signaling pathway, along with more severe cognitive deficits. This observation suggests an intrinsic link between ApoE ε4, GSK‐3β, and cognitive dysfunction. However, the precise mechanisms by which ApoE ε4 influences GSK‐3β activity and exacerbates brain pathology and cognitive decline in T2DM patients remain poorly understood.

Methods

To investigate these mechanisms, we developed T2DM mouse models by generating humanized ApoE ε3/ε3 and ε4/ε4 knock‐in mice. The mice were subjected to a high‐fat diet combined with multiple low‐dose intraperitoneal streptozotocin injections to induce T2DM. We then assessed GSK‐3β expression, AD‐like pathologies, and cognitive functions in these models.

Results

We observed that GSK‐3β activity was significantly upregulated in ApoE4 mice, accompanied by disruption of the insulin signaling pathway. Notably, ApoE4‐T2DM mice exhibited exacerbated AD‐related pathologies, including increased accumulation of hyperphosphorylated tau, neuroinflammation, and synaptic loss. These changes were correlated with more severe cognitive impairments compared with ApoE3‐T2DM or ApoE4 mice. Furthermore, inhibition of GSK‐3β activity using the selective inhibitor 9‐ING‐41 effectively ameliorated both AD‐like pathologies and cognitive deficits in ApoE4‐T2DM mice.

Conclusions

Our findings suggest that ApoE4 exacerbates AD pathogenesis by activating GSK‐3β. Furthermore, targeting GSK‐3β may offer a promising therapeutic strategy to halt the progression from T2DM to AD, providing new insights into potential interventions for patients at risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycogen Synthase Kinase 3 betaApolipoprotein E4Diabetes Mellitus, Type 2Alzheimer DiseaseCognitive DysfunctionDiabetes Mellitus, ExperimentalAnimalsMiceMice, TransgenicMaleUp-RegulationMice, Inbred C57BLDisease Models, AnimalHumanstau Proteins

Stichwörter der Autor:innen

9‐ING‐41Alzheimer's diseaseApoEglycogen synthase kinase‐3βtype 2 diabetes mellitus

Substanzen

Glycogen Synthase Kinase 3 betaApolipoprotein E4tau ProteinsGsk3b protein, mouse

Autor:innen und Institutionen

  • Key Laboratory of Ministry of Education for Neurological Disorders, Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Neurology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
  • Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
  • Key Laboratory of Ministry of Education for Neurological Disorders, Department of Endocrine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Co-Innovation Center of Neuroregeneration, Nantong University, Nantong, China.
  • Hubei Key Laboratory of Cognitive and Affective Disorders, Jianghan University, Wuhan, China.

ORCID-Profile: Yuying Wang, Yang Gao, Haibo Xu

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation General Program
  • Guangdong Provincial Key S&T Program

Zitieren

APA

Wang, Y., Gao, Y., Wang, Y., Zhang, F., Sun, F., Wang, X., Xie, J., Xu, Z., Zhang, J., Xu, H., Zhang, Y., & Wang, J. Z. (2025). ApoE4 Upregulates GSK ‐3β to Aggravate Alzheimer‐Like Pathologies and Cognitive Impairment in Type 2 Diabetic Mice. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70575

Vancouver

Wang Y, Gao Y, Wang Y, Zhang F, Sun F, Wang X, et al. ApoE4 Upregulates GSK ‐3β to Aggravate Alzheimer‐Like Pathologies and Cognitive Impairment in Type 2 Diabetic Mice. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70575

BibTeX
@article{Wang2025,
  author = {Wang, Yuying and Gao, Yang and Wang, Yarong and Zhang, Fuqiang and Sun, Fei and Wang, Xin and Xie, Jiazhao and Xu, Zhipeng and Zhang, Junjian and Xu, Haibo and Zhang, Yao and Wang, Jian-Zhi},
  title = {ApoE4 Upregulates GSK ‐3β to Aggravate Alzheimer‐Like Pathologies and Cognitive Impairment in Type 2 Diabetic Mice},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2025},
  doi = {10.1111/cns.70575}
}
Kostenlos starten →